Rohini R. Roshmi
AB T6G1C9, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.
Journal: Cardiovascular research
Published: September 06, 2024
Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells.
Journal: Molecular therapy. Nucleic acids
Published: August 16, 2024
DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function.
Journal: Nature communications
Published: April 02, 2024
Viltolarsen: From Preclinical Studies to FDA Approval.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: November 18, 2022
Genetic Approaches for the Treatment of Giant Axonal Neuropathy.
Journal: Journal of personalized medicine
Published: October 31, 2022
Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1R206H Transcript and Inhibit Osteogenic Differentiation.
Journal: Nucleic acid therapeutics
Published: January 27, 2022
Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 15, 2021
Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience.
Journal: Clinical pharmacology : advances and applications
Published: September 20, 2021
Viltolarsen for the treatment of Duchenne muscular dystrophy.
Journal: Drugs of today (Barcelona, Spain : 1998)
Published: November 14, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026